High Risk Myelodysplastic Syndrome
specificMyelodysplastic syndrome with more than 4.5 to 6 points, according to the revised International Prognostic Scoring System (IPSS-R).
11
Centers
9
Active Trials
—
Cancer Funding
Top Centers for High Risk Myelodysplastic Syndrome(11)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 58.6 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 58.6 |
| 3 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive Active Research Program | 58.6 |
| 4 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 58.6 |
| 5 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 58.6 |
| 6 | University of Illinois Cancer CenterChicago, IL Active Research Program | 58.6 |
| 7 | Boston University Cancer CenterBoston, MA Active Research Program | 58.6 |
| 8 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 58.6 |
| 9 | Georgia Cancer Center, Augusta UniversityAugusta, GA Active Research Program | 58.6 |
| 10 | UNC Lineberger Comprehensive Cancer CenterChapel Hill, NC NCI Comprehensive | 36.1 |
| 11 | NCI Clinical | 36.1 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →